CYTO — Altamira Therapeutics Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro CapSucker Stock
- $6.14m
- $12.62m
- CH₣0.31m
Annual income statement for Altamira Therapeutics, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0.064 | 0.306 |
Cost of Revenue | |||||
Gross Profit | — | — | — | -0.199 | -0.207 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 11 | 7.26 | 5.28 | 16.8 | 26.4 |
Operating Profit | -11 | -7.26 | -5.28 | -16.8 | -26.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11.3 | -6.83 | -8.22 | -17 | -26.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11.5 | -6.63 | -8.2 | -17.1 | -26.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -11.5 | -6.63 | -8.2 | -17.1 | -26.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.5 | -6.63 | -8.2 | -17.1 | -26.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -289 | -45.6 | -27.3 | -22.3 | -19.6 |